KIMS enters into agreement to manage Splendid Hospitals, Hyderabad
Krishna Institute of Medical Sciences Ltd enters into agreement with Splendid Hospitals
Krishna Institute of Medical Sciences Ltd enters into agreement with Splendid Hospitals
This strategic partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
Subscribe To Our Newsletter & Stay Updated